Ajanta Pharma has reported results for second quarter ended September 30, 2016.
The company has reported 27.42% rise in its net profit at Rs 120.95 crore for the quarter under review as compared to Rs 94.92 crore for the same quarter in the previous year. Total income of the company increased by 16.07% at Rs 484.42 crore for the quarter under review as compared Rs 417.36 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported 26.31% rise in its net profit after taxes, minority interest and share of profit of associates at Rs 130.66 crore for the quarter ended September 30, 2016 as compared to Rs 103.44 crore for the same quarter in the previous year. Total Income of the company has increased by 16.66% to Rs 522.48 crore for quarter under review from Rs 447.86 crore for the quarter ended September 30, 2015.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: